Concepedia

Author

Siddhartha Goutam

University of CalgaryORCID

Also Known As

S. Goutam, SIDDHARTHA GOUTAM, Savarna Goutam, Sid Goutam, Siddhartha Goutam

30

Publications

372

Citations

8

H-Index

15

Concepts

All Affiliations

University of CalgaryUniversity of Alberta
SG

About

Siddhartha Goutam is an author at University of Calgary specializing in oncology, cancer therapeutics, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

39

2

Cancer Therapeutics

2

2

39

3

Pathology

1

1

13

4

Pharmacology

1

1

13

5

Immunotherapy

1

1

26

Siddhartha Goutam

×

7

Publications

229

Citations

7

H-Index

YearCitations

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy

Alexander Watson, Siddhartha Goutam, Igor Stukalin,

JAMA Network Open

2022

58

Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells

Nicholas Jette, Suraj Radhamani, Greydon Arthur,

British Journal of Cancer

2019

48

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials

Chun Loo Gan, Igor Stukalin, Daniel E. Meyers,

European Journal of Cancer

2021

46

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

Heidi A.I. Grosjean, Samantha Dolter, Daniel E. Meyers,

Current Oncology

2021

27

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors

Daniel E. Meyers, Meghann Pasternak, Samantha Dolter,

JTO Clinical and Research Reports

2023

26

ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738

Nicholas Jette, Suraj Radhamani, Ruiqiong Ye,

Genome Instability & Disease

2020

13

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors

Igor Stukalin, Vishal Navani, Mehul Gupta,

The Oncologist

2023

11

Page 1